Relmada Therapeutics appointed Paul Kelly as Chief Operating Officer effective January 1, 2025, with a salary of $476,000 and potential bonuses, while also amending employment agreements for other executives to align with cost control measures, including suspension of retention payments and no salary increases or bonuses for fiscal 2025.